ROPN1 and neoplasm: For these reasons, the potential to achieve increased tumour coverage by targeting NY-ESO-1, ROPN1A and ROPN1B combined makes these immunogenic CTAgs highly compatible for combination in a cancer vaccine with the potential to generate synergistic immune responses to the tumour.